Refine by
Health Administration Articles & Analysis
81 news found
House Appropriations Committee’s Fiscal Year 2027 Military Construction and Veterans Affairs (MilCon/VA) appropriations report highlights the role of regenerative wound technologies, including fish-skin-derived products, in limb preservation and value-driven care within the Veterans Health Administration (VHA).The report acknowledges the ongoing burden of ...
ByKerecis
Boston: “According to the latest BCC Research study, the demand for Medical Kiosks: Global Market and Forecasts is estimated to increase from $1.4 billion in 2022 to reach $3.2 billion by 2028, at a compound annual growth rate (CAGR) of 14.8% from 2022 through 2028.” The comprehensive report on the medical kiosks market delivers a thorough analysis of its current landscape and future ...
The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care diseases and community medical threats, announced today that it has received a contract from the ...
“Though diabetic foot ulcer infections aren’t traditionally thought of as a combat related wound suffered in the field, diabetes is a serious disease that affects a significantly high percentage of our veterans and its complications such as DFI contributes to decline in health, quality of life and are responsible for the vast majority of non-combat amputations among ...
ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies has joined as a full partner the Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC) including the National Institutes of Health (NIH) and the Food and Drug ...
(“LucidDx Labs”), has entered into a participating provider agreement with MediNcrease Health Plans, LLC (“MediNcrease”), a national, directly-contracted, multi-specialty PPO provider network with over 8 million lives covered through its clients and payers, which include regional and national health plans, insurance companies, third party ...
The narcolepsy drug Wakix can now be prescribed to patients in China with urgent unmet medical needs BOSTON, Mass., and Boao, Hainan, China, May 07, 2021 – Citrine Medicine, a China-based rare disease therapeutics company, today announced that the narcolepsy therapy Wakix® (pitolisant) has been approved by the Health Commission and Medical Products ...
Medical device and technology company Lazurite today announced an agreement with CHAMPS Group Purchasing (GPO), a business affiliate of The Center for Health Affairs, through which CHAMPS GPO will offer Lazurite’s products to its members across the United States. The partnership follows Lazurite’s receiving 510(k) market clearance by the U.S. Food and Drug ...
The SmartMat, which also has the Seal of Approval from the American Podiatric Medical Association, has already been used by thousands of patients through partnerships with leading risk-based healthcare providers and regional and national health plans, such as the Veterans Health Administration. “The patients we serve at Podimetrics are ...
The approval makes this innovative technology readily available for order by any clinician or administrator at any VA facility nationwide,” said Vince Proffitt, President and CEO of Spartan Medical. ? The Veterans Health Administration (VHA) is the largest integrated health care system in the US, providing care at ...
Transitioning from his role as a 4D Path advisory board member, world-renowned cancer oncologist, health consultant, and entrepreneur Dr. Teich will now serve as 4D Path’s Chief Global Strategist. ...
"In 2022, we expect to benefit from guidance issued last week by the Health Resources and Services Administration and the U.S. Department of Labor, which is an important step toward securing access to Phexxi for all women at zero copay without overly burdensome denials or being forced to try other contraceptive products first. ...
“Patients who experience a diabetic foot ulcer tend to be medically complex with multiple other chronic health conditions, putting them at higher risk for hospitalization and death, and they’re often among the costliest patients in our health care system,” said Dr. ...
(NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor on their separately-issued updated guidance related to contraceptive access. The new guidance specifies that most insurers and pharmacy benefit managers (PBMs) must provide coverage, with no out-of-pocket costs to women, for U.S. Food and Drug ...
Wendt is Board-certified by the European Board of Cardiothoracic Surgery (FETCS) and also obtained his Master of Health Business Administration (MHBA) from the Friedrich-Alexander-University School of Business in Erlangen-Nuremberg, Germany. ...
Preceding BCBSA, Serota was president and CEO of Chicago-based Rush Prudential Health Plans. Serota is a founding member of the National Business Group on Health's Institute on Healthcare Costs and Solutions, a board member of Brain Research Foundation, and an advisory board member of Paragon Biosciences. ...
In that role he led the commercialisation of the company’s suite of tests for biomarkers of organ rejection, including the flagship product TruGraf®, the only biomarker test for kidney transplant recipients approved for reimbursement by US national health insurance system administrator, the Centers for Medicare & Medicaid Services (CMS). ...
“Our collaboration will positively impact our members’ mental and physical health and will help lower health care costs by preventing hospitalizations, emergency department visits, and outpatient or physician office ...
The Company began regulatory discussions on QIXLEEF™ with both the U.S. Food and Drug Administration (FDA) and Health Canada in mid-2016. This included obtaining a product jurisdiction decision for the regulation of QIXLEEF™ as a drug-device combination product. ...
Each year, thousands of employees are blinded from work-related eye injuries that could have been prevented with the proper selection and use of eye and face protection according to the Occupational Safety and Health Administration (OSHA). OSHA standards require employers to ensure the safety of all employees in the work environment and this includes eye and face ...